In vivo metabolomics identifies CD38 as an emergent vulnerability in LKB1-mutant lung cancer
J. Deng, D. H. Peng, D. Fenyo, Y. Hao, A. Lopez, D. Levin, M. Meynardie, M. Quinteros, M. Ranieri, S. Sahu, S. Lau, E. Shum, V. Velcheti, S. R. Punekar, N. Rekhtman, , K.-K. Wong
The paper identifies CD38 as a therapeutic target in LKB1-mutant lung cancer through in vivo metabolomics and shows that targeting CD38 inhibits tumor growth.
bioRxiv · Apr 18, 2023 · PreprintCancer Biology